Healthy Participants
Conditions
Brief summary
The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants. Study participation may last up to 22 weeks and up to approximately 18 study visits.
Interventions
DRUGLY4060874
Administered SC
DRUGPlacebo
Administered SC
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Are overtly healthy as determined by medical evaluation, including medical history and physical examination. * Have a body mass index in the range of 20 to 29.9 kilogram per meter squared (kg/m²), inclusive, at screening. * To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China. * To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all the participants' biological grandparents must be of exclusive Japanese descent and born in Japan.
Exclusion criteria
* Have a history of or have been diagnosed with Type 1 or Type 2 diabetes mellitus. * Have hemoglobin A1c (HbA1c) \> 6.4% or 46 millimoles/mole (mmol/mol) at screening. * Have taken approved, including over the counter (OTC) or prescribed, medication or investigational medication for weight loss, including GLP-1 receptor agonists, within the previous 3 months of study screening. * Have had surgical treatment for obesity. * Are actively participating in a weight loss program or intend to initiate an intensive diet and/or exercise program during the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Baseline up to 22 Weeks | Number of participants with one or more TEAEs and SAEs. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time (AUC) of LY4060874 | PK: Part A: Baseline up to 13 weeks; Part B and C: Baseline up to 18 weeks | PK: Area Under the Concentration Versus Time (AUC) of LY4060874 |
| PK: Maximum Observed Concentration of LY4060874 | PK: Part A: Baseline up to 13 weeks; Part B and C: Baseline up to 18 weeks | PK: Cmax of LY4060874 |
Countries
Singapore, United States
Contacts
STUDY_DIRECTOR1-877-CTLILLY (1-877-285-4559) or 3176154559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
Outcome results
None listed